|
000
| 02310nam 2200301za 4500 |
|---|
| 001 | 9.833924 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107150324 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 170427s2017 onc ob f000 0 eng d |
|---|
| 020 | |a978-0-660-08010-9 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aHP40-177/2017E-PDF |
|---|
| 245 | 00|aCanadian HIV Vaccine Initiative achievements report |h[electronic resource]. |
|---|
| 260 | |aOttawa : |bPublic Health Agency of Canada, |c2017. |
|---|
| 300 | |ai, 29 p. |
|---|
| 500 | |aIssued also in French under title: Rapport des réalisations Initiative canadienne de vaccin contre le VIH. |
|---|
| 500 | |aCover title. |
|---|
| 500 | |a"Publication date: March 2017"--Verso of cover. |
|---|
| 504 | |aIncludes bibliographical references. |
|---|
| 520 | |a"The Canadian HIV Vaccine Initiative (CHVI), which concludes in March 2017, has been a unique collaboration between the Government of Canada (GoC) (the Public Health Agency of Canada (PHAC); Health Canada (HC); the Canadian Institutes of Health Research (CIHR); Innovation, Science and Economic Development (ISED); the National Research Council (NRC); and Global Affairs Canada (GAC)) and the Bill & Melinda Gates Foundation (BMGF) to further strengthen global efforts to accelerate the development of a safe, effective, affordable and globally accessible HIV vaccine. An investment of $139M (GoC - $111M from existing resources; BMGF - $28M) was made to support CHVI activities since 2007, a small investment considering that, in 2009, the total costs of HIV in Canada (loss of quality of life, health care costs, and productivity loss) was estimated at just over $4 billion. Overall, CHVI activities served to advance global research and development (R&D) on HIV vaccine research and other HIV-related research, and to increase the visibility of Canadian HIV vaccine research, both domestically and internationally … "--Executive summary, p. 1. |
|---|
| 692 | 07|2gccst|aAIDS (disease) |
|---|
| 692 | 07|2gccst|aImmunization |
|---|
| 692 | 07|2gccst|aResearch and development |
|---|
| 710 | 2 |aPublic Health Agency of Canada. |
|---|
| 775 | 08|tRapport des réalisations Initiative canadienne de vaccin contre le VIH |w(CaOODSP)9.833925 |
|---|
| 856 | 40|qPDF|s351 KB|uhttps://publications.gc.ca/collections/collection_2017/aspc-phac/HP40-177-2017-eng.pdf |
|---|